BIOCRYST PHARMACEUTICALS INC
Price data unavailable
Track BCRX in your trading journalAbout BIOCRYST PHARMACEUTICALS INC
BIOCRYST PHARMACEUTICALS INC (BCRX) is a US-listed equity tracked across major market indices. BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
The company reports trailing twelve-month revenue of $25.19M and net loss of $721.81M. Key metrics include a return on equity of 130.3%, a debt-to-equity ratio of -1.84.
FINOTAUR provides free research summaries, news aggregation, and fundamentals for BCRX to support both active traders and long-term investors.
Fundamentals
| Revenue (TTM) | $25.19M |
| Net Income (TTM) | $-721.81M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | 130.33% |
| Debt-to-Equity | -1.84 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·May 6
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
- GlobeNewswire Inc.·May 4
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
- GlobeNewswire Inc.·Apr 6
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
Want real-time analysis on BCRX?
Track it free in your trading journal. Log trades, tag setups, and review your edge.